MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Начало・Списък с акции・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

24.99 0.28

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.63

Максимум

25.14

Ключови измерители
By Trading Economics
Приходи	-85K 53M
Продажби	4.2M 153M
P/E Средно за сектора	14.155 56.063
EPS	0.68
Марж на печалбата	34.53
Служители	182
EBITDA	612K 81M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+39.73% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-41M 2.9B
Предишно отваряне	24.71
Предишно затваряне	24.99

Настроения в новините

By Acuity

50%

170 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

N/A / 24.28 Подкрепа & съпротива

Catalyst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.04.2026 г., 23:17 ч. UTC

Печалби

Samsung Forecasts Record First-Quarter Operating Profit

6.04.2026 г., 23:00 ч. UTC

Горещи акции

Stocks to Watch: Health Insurers, Mawson, Owlet

6.04.2026 г., 22:13 ч. UTC

Значими двигатели на пазара

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6.04.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6.04.2026 г., 17:09 ч. UTC

Значими двигатели на пазара

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6.04.2026 г., 16:56 ч. UTC

Значими събития в новините

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6.04.2026 г., 14:47 ч. UTC

Значими двигатели на пазара

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6.04.2026 г., 23:58 ч. UTC

Пазарно говорене

Значими събития в новините

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6.04.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6.04.2026 г., 23:15 ч. UTC

Пазарно говорене

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6.04.2026 г., 22:52 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

6.04.2026 г., 22:52 ч. UTC

Пазарно говорене

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6.04.2026 г., 22:14 ч. UTC

Пазарно говорене

Correction to Live Cattle Futures Article

6.04.2026 г., 20:56 ч. UTC

Пазарно говорене

Mexican Private Consumption Fell in January -- Market Talk

6.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

6.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.04.2026 г., 19:58 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.04.2026 г., 19:58 ч. UTC

Пазарно говорене

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6.04.2026 г., 19:11 ч. UTC

Пазарно говорене

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6.04.2026 г., 19:06 ч. UTC

Пазарно говорене

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6.04.2026 г., 19:03 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

6.04.2026 г., 19:03 ч. UTC

Пазарно говорене

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6.04.2026 г., 18:36 ч. UTC

Придобивния, сливания и поглъщания

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6.04.2026 г., 17:59 ч. UTC

Пазарно говорене

Значими събития в новините

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6.04.2026 г., 17:13 ч. UTC

Придобивния, сливания и поглъщания

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6.04.2026 г., 16:33 ч. UTC

Пазарно говорене

Oil Futures Steady as Market Awaits Trump -- Market Talk

6.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.04.2026 г., 14:59 ч. UTC

Печалби

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Catalyst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

39.73% нагоре

12-месечна прогноза

Среден 34.5 USD 39.73%

Висок 35 USD

Нисък 33 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Catalyst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Catalyst Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 24.28Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

170 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.